Alpha This is a work in progress and may change. Your feedback is very welcome.
  


7DC6

Aime-128 binding "NGYNFFSTF" at 2.68Å resolution

Data provenance

Structure downloaded from PDB Europe using the Coordinate Server. Aligned to residues 1-180 of 1HHK2 using the CEALIGN3 function of PyMol4. Chain assigment using a Levenshtein distance5 method using data from the PDBe REST API6. Organism data from PDBe REST API. Data for both of these operations from the Molecules endpoint. Structure visualised with 3DMol7.

Information sections


Complex type

Class i with peptide

1. Beta 2 microglobulin
['B', 'D']
2. Class I alpha
Aime-128
['A', 'C']
3. Peptide
NGYNFFSTF
['E', 'F']

Species


Locus / Allele group


Publication

Crystal structure of the giant panda MHC class I complex: First insights into the viral peptide presentation profile in the bear family.

Yuan H, Ma L, Zhang L, Li X, Xia C
Protein Sci (2020) 29, 2468-2481 [doi:10.1002/pro.3980]  [pubmed:33078460

Background

Initiating ivabradine in acute heart failure (HF) is still controversial.

Hypothesis

Ivabradine might be effective to be added in acute but hemodynamically stable HF.

Methods

A retrospective cohort of hemodynamically stable acute HF patients was enrolled from January 2018 to January 2020 and followed until July 2020. The primary endpoints were all-cause mortality and rehospitalization for HF. Secondary endpoints included heart rate (HR), cardiac function measured by New York Heart Association (NYHA) class, and left ventricular ejection fraction (LVEF) and adverse events, which were compared between patients with or without ivabradine.

Results

A total of 126 patients were enrolled (50 males, median age 54 years, 81% with decompensated HF, median follow-up of 9 months). In patients treated with ivabradine, although baseline HRs were higher than the reference group (96 vs. 80 bpm), they were comparable after 3 months; more patients tolerated high doses of β-blockers (27% vs. 7.9%), improved to NYHA class I function (55.6% vs. 23.8%) and exhibited normal LVEFs (37.8% vs. 14.3%) than the reference group (all p < .05). Ivabradine was associated with a significant reduction of rehospitalization for HF than the reference group (25.4% vs.61.9%), with longer event-free survival times (hazard ratio: 0.45, 95% confidence interval [CI]: 0.25-0.79), and was related with primary endpoints negatively (hazard ratio 0.51, 95% CI: 0.28-0.91) (all p < .05).

Conclusion

In patients with acute but hemodynamically stable HF, ivabradine may significantly reduce HR, improve cardiac function, and reduce HF rehospitalization.

Structure deposition and release

Deposited: 2020-10-23
Released: 2021-06-16
Revised: 2021-06-16

Data provenance

Publication data retrieved from PDBe REST API8 and PMCe REST API9

Other structures from this publication


Peptide details

Length: Nonamer (9 amino acids)

Sequence: NGYNFFSTF

Interactive view
Cutaway side view (static)
Surface top view (static - coloured by atom property)
Cutaway top view (static)

Data provenance

MHC:peptide complexes are visualised using PyMol. The peptide is superimposed on a consistent cutaway slice of the MHC binding cleft (displayed as a grey mesh) which best indicates the binding pockets for the P1/P5/PC positions (side view - pockets A, E, F) and for the P2/P3/PC-2 positions (top view - pockets B, C, D). In some cases peptides will use a different pocket for a specific peptide position (atypical anchoring). On some structures the peptide may appear to sterically clash with a pocket. This is an artefact of picking a standardised slice of the cleft and overlaying the peptide.


Peptide neighbours

P1 ASN

ARG63
ASN64
MET6
TYR8
GLU164
TYR60
TYR172
TYR160
ILE67
TRP168
P2 GLY

TYR160
ILE67
TYR10
ASN64
TYR8
P3 TYR

ILE67
ARG156
TYR157
TYR10
TRP98
HIS100
GLU153
TYR160
ASN71
P4 ASN

ASP70
GLU153
ARG66
ASN71
ILE67
ARG156
P5 PHE

TRP134
ARG156
TRP148
TRP98
GLU153
ASP70
SER115
ALA74
ASN71
P6 PHE

ALA74
ARG156
GLU153
ASP70
P7 SER

GLU153
ASP78
ALA74
ALA151
TRP148
P8 THR

VAL77
THR144
LYS147
TRP148
ASP78
ALA74
P9 PHE

TYR124
ILE96
TYR85
THR144
ILE143
THR81
ALA82
LEU117
ASP78
LYS147
TRP148

Colour key

Aromatic Hydrophobic Acidic Basic Neutral/polar

Data provenance

Neighbours are calculated by finding residues with atoms within 5Å of each other using BioPython Neighboursearch module. The list of neighbours is then sorted and filtered to inlcude only neighbours where between the peptide and the MHC Class I alpha chain.

Colours selected to match the YRB scheme. [https://www.frontiersin.org/articles/10.3389/fmolb.2015.00056/full]


Binding cleft pockets


Peptide sidechain binding pockets (static)
Peptide terminii and backbone binding residues (static)
A Pocket

TYR159
GLU163
TRP167
TYR171
MET5
TYR59
ASN63
ILE66
TYR7
B Pocket

ALA24
VAL34
MET45
ASN63
ILE66
ALA67
TYR7
ASN70
TYR9
HIS99
C Pocket

ASN70
ALA73
PHE74
TYR9
TRP97
D Pocket

SER114
ARG155
TYR156
TYR159
VAL160
HIS99
E Pocket

SER114
TRP147
GLU152
TYR156
TRP97
F Pocket

LEU116
TYR123
THR143
LYS146
TRP147
ASP77
THR80
ALA81
TYR84
ILE95

Colour key

Binds N-terminus Binds P1 backbone Binds P2 backbone Binds PC-1 backbone Binds C-terminus

Data provenance

N-/C-terminus and peptide backbone binding residues are assigned according to previously published information and pockets are assigned according to an adaptation of a previously published set of residues. All numbering is currently that of the 'canonical' structures of human and mouse MHC Class I molecules.

Chain sequences

1. Beta 2 microglobulin
Beta 2 microglobulin
        10        20        30        40        50        60
MVQHAPKIQVYSRHPAENGKPNFLNCYVSGFHPPEIEIDLLKNGEKMKAEQSDLSFSKDW
        70        80        90
TFYLLVHTEFTPNGQDEFSCRVKHVTLSEPQIIKWERDN

2. Class I alpha
Aime-128
        10        20        30        40        50        60
GSHSMRYFYTAVSRPGRGEPRFIAVGYVDDTQFVRFDSDSASRRMEPRAPWIEQEGPEYW
        70        80        90       100       110       120
DRNTRIAEDNAQAFRVDLQTALRYYNQSEAGSHTIQWMHGCDVGPDGRLLRGYSQLAYDG
       130       140       150       160       170       180
ADYIALNEDLRSWTAADTAAQITRRKWEAAGEAERYRNYVEGECVEWLRRYLENGKETLQ
       190       200       210       220       230       240
RAETPDTRVTRHPISDQKVTLRCWALGFYPAEITLTWQQDGEDLTQDTELVETRPAGDGT
       250       260       270
FQKWAAVVVPSGQEQRYTCHVQHEGLPEPLTRSWE

3. Peptide
NGYNFFSTF


Data provenance

Sequences are retrieved via the Uniprot method of the RSCB REST API. Sequences are then compared to those derived from the PDB file and matched against sequences retrieved from the IPD-IMGT/HLA database for human sequences, or the IPD-MHC database for other species. Mouse sequences are matched against FASTA files from Uniprot. Sequences for the mature extracellular protein (signal petide and cytoplasmic tail removed) are compared to identical length sequences from the datasources mentioned before using either exact matching or Levenshtein distance based matching.


Downloadable data

Data can be downloaded to your local machine from the links below.
Clicking on the clipboard icon will copy the url for the data to your clipboard.
This can then be used to load the structure/data directly from the url into an application like PyMol (for 3D structures) using the load command:
   e.g. load http://www.histo.fyi/structures/downloads/1hhk_1_peptide.cif
or in the case of JSON formatted files to retrieve it and use it as part of notebooks such as Jupyter or GoogleColab.
Please take note of the data license. Using data from this site assumes that you have read and will comply with the license.

Complete structures

Aligned structures [cif]
  1. 7DC6 assembly 1  
  2. 7DC6 assembly 2  

Components

MHC Class I alpha chain [cif]
  1. 7DC6 assembly 1  
  2. 7DC6 assembly 2  
MHC Class I antigen binding domain (alpha1/alpha2) [cif]
  1. 7DC6 assembly 1  
  2. 7DC6 assembly 2  
Peptide only [cif]
  1. 7DC6 assembly 1  
  2. 7DC6 assembly 2  

Derived data

Data for this page [json]
https://api.histo.fyi/v1/structures/7dc6

Data license

The data above is made available under a Creative Commons CC-BY 4.0 license. This means you can copy, remix, transform, build upon and redistribute the material, but you must give appropriate credit, provide a link to the license, and indicate if changes were made.
If you use any data downloaded from this site in a publication, please cite 'https://www.histo.fyi/'. A preprint is in preparation.

Footnotes